An oncological view on the blood-testis barrier.
暂无分享,去创建一个
Joost Bart | Elisabeth G E de Vries | Harry J M Groen | H. Groen | H. Hollema | J. Bart | E. D. de Vries | W. Vaalburg | N. Hendrikse | D. Sleijfer | Willem Vaalburg | Winette T A van der Graaf | N Harry Hendrikse | Harry Hollema | Dirk T Sleijfer | W. V. D. van der Graaf | Harry JM Groen | N. Hendrikse | Dirk T Sleijfer | Elisabeth GE de Vries
[1] G. Perry,et al. Barrier properties of testis microvessels. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[2] V. Dixit,et al. Death receptors: signaling and modulation. , 1998, Science.
[3] R. Advani,et al. Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) , 1999 .
[4] D. Altman,et al. Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994. , 1996, British journal of urology.
[5] L. Dunkel,et al. Fas regulates germ cell apoptosis in the human testis in vitro. , 1999, American journal of physiology. Endocrinology and metabolism.
[6] A. Sartorelli,et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[7] C Tondini,et al. Diffuse large-cell lymphoma of the testis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Vaylet,et al. Pulmonary Metastasis Secondary to Burned-Out Testicular Tumor , 2000, Respiration.
[9] R. Oliver,et al. Current opinion in germ cell cancer 2000. , 2000, Current opinion in oncology.
[10] J. Beijnen,et al. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. , 1996, Journal of the National Cancer Institute.
[11] J. Wijnholds,et al. Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage , 1998, The Journal of experimental medicine.
[12] G. Masera,et al. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: a 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). , 1995, Medical and pediatric oncology.
[13] A. Covelli. Modulation of multidrug resistance (MDR) in hematological malignancies. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Nagata,et al. Testicular FasL is expressed by sperm cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Kerr. 1 Functional cytology of the human testis , 1992 .
[16] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[17] W Vaalburg,et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. , 1999, Cancer research.
[18] M. Kool,et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.
[19] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Tsuruo,et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.
[21] D. Bellgrau,et al. A role for CD95 ligand in preventing graft rejection , 1995, Nature.
[22] F. Baas,et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. , 1993, Cancer research.
[23] M. Kool,et al. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. , 1999, Cancer research.
[24] T. Flotte,et al. Immunohistochemical characterization of seminoma and its inflammatory cell infiltrate. , 1987, Human pathology.
[25] R. Elton,et al. Immunocompetent cells in human testis in health and disease. , 1987, Fertility and sterility.
[26] J. Pont,et al. Fertility after chemotherapy for testicular germ cell cancer. , 1997, Fertility and sterility.
[27] H. Kluin-Nelemans,et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. , 2001, Journal of the National Cancer Institute.
[28] J. Cox,et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Skakkebaek,et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] D. Dearnaley,et al. Fertility after chemotherapy for testicular germ cell cancers. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] B. Sikic,et al. Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations , 1993, Cancer.
[32] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[34] T. Tsuruo,et al. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue , 1990 .
[35] W. Whitmore,et al. Effect of treatment on fertility and sexual function in males with metastatic nonseminomatous germ cell tumors of testis , 1985, American journal of clinical oncology.
[36] E. Bruera,et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. , 1998, British Journal of Cancer.
[37] W Vaalburg,et al. Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography , 1998, British journal of pharmacology.
[38] M. Wiley,et al. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail--chick transplantation chimeras. , 1981, Developmental biology.
[39] G. W. Gross,et al. Metastatic seminoma with regression of testicular primary: ultrasonographic detection. , 1986, The Journal of urology.
[40] U. Brinkmann,et al. Frequency of C3435T polymorphism of MDR1 gene in African people , 2001, The Lancet.
[41] S. Byers,et al. The blood‐testis barrier and sertoli cell junctions: Structural considerations , 1992, Microscopy research and technique.
[42] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[43] G. Peters,et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Sharpe,et al. Response of the seminiferous epithelium of the rat testis to withdrawal of androgen: evidence for direct effect upon intercellular spaces associated with Sertoli cell junctional complexes , 1993, Cell and Tissue Research.
[45] R. Kramer,et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.
[46] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[47] D. Fawcett,et al. The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium. , 1970, Biology of reproduction.
[48] R. Evers,et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.
[49] Wan Ariffin Bin Abdullah,et al. Med Pediatr Oncol , 1999 .
[50] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[51] I. Bechmann,et al. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: Evidence for the existence of an immunological brain barrier , 1999, Glia.
[52] P. Kuchel,et al. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. , 1999, International review of cytology.
[53] A. Renshaw,et al. Burned-out primary testicular cancer: sonographic and pathological characteristics. , 1996, The Journal of urology.
[54] L. Russell,et al. Observations on the inter-relationships of Sertoli cells at the level of the blood- testis barrier: evidence for formation and resorption of Sertoli-Sertoli tubulobulbar complexes during the spermatogenic cycle of the rat. , 1979, The American journal of anatomy.
[55] R. Bergmann,et al. Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells , 1998, Journal of neurochemistry.
[56] H. Hoekstra,et al. Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer , 1997, Annals of Surgical Oncology.
[57] D. Miller,et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. , 1998, Biochemical and biophysical research communications.
[58] G. Mead,et al. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? , 1995, Cancer.
[59] A. Abbas,et al. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. , 1998, Journal of immunology.
[60] N. Rucci,et al. Fas and Fas ligand expression in fetal and adult human testis with normal or deranged spermatogenesis. , 2000, The Journal of clinical endocrinology and metabolism.
[61] D. Keppler,et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.
[62] W Vaalburg,et al. The blood-brain barrier and oncology: new insights into function and modulation. , 2000, Cancer treatment reviews.
[63] N. Yamamoto,et al. Induction of blood–brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors , 1999, Neuroscience Research.
[64] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[65] M. Kool,et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.
[66] S. Thorgeirsson,et al. Multidrug resistance gene family and chemical carcinogens. , 1991, Pharmacology & therapeutics.
[67] D D Breimer,et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.
[68] K. Liu,et al. In situ observation of inflammatory cell-tumor cell interaction in human seminomas (germinomas): light, electron microscopic, and immunohistochemical study. , 1992, Human pathology.
[69] W. Kamps,et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). , 1999, Blood.
[70] C. Beglinger,et al. Evidence for Different ABC-Transporters in Caco-2 Cells Modulating Drug Uptake , 1999, Pharmaceutical Research.
[71] K. Boekelheide,et al. THE FAS SYSTEM IS A KEY REGULATOR OF GERM CELL APOPTOSIS IN THE TESTIS , 1997 .